Genmab A+s

Brian Elliott

Tahamtan Ahmadi

Esther C W Breij

Ida Hiemstra

Christopher W L Chiu

Maria N Jure-Kunkel

Christopher Chiu

Ada Azaryan

Roberto Oliveri

Dena Demarco

Tommy Li

Manish Gupta

Jenny Jianlin Chen

The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).

Bispecific antibodies against CD3 and CD20

Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.

Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia

Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma

Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.

Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma

Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).

Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.

Growing community of inventors

Hoboken, NJ, United States of America

Brian Elliott